Neurokin gets ANR support for Strokinin project
The neuroprotective efficacy of NK-102 is based on its dual mechanism of action. After a brain injury NK-102, firstly blocks neuronal apoptosis and also reduces inflammation by inhibiting
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.